Immune Pharmaceuticals Inc. (IMNP) Stock Price, Quote, News and Overview
NASDAQ:IMNP - Nasdaq -
IMNP Quote, Performance and Key Statistics
NASDAQ:IMNP (9/10/2018, 5:44:59 PM)
0.064
-0.1 (-61.21%)
The current stock price of IMNP is 0.064 null. In the past month the price decreased by -66.32%. In the past year, price decreased by -95.87%.
About IMNP
Company Profile
Immune Pharmaceuticals, Inc. is a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases. Immune's lead program, bertilimumab, is a first-in-class, human monoclonal antibody that binds eotaxin-1, a chemokine that attracts eosinophils to the site of inflammation. By blocking eotaxin-1, bertilimumab may prevent the migration and activation of eosinophils and other cells, thus blocking an important inflammatory pathway active in a variety of allergic and immune diseases. Bertilimumab has shown promising clinical activity in bullous pemphigoid and has been studied in other conditions including allergic rhinitis and ulcerative colitis, and may have application in other diseases, including atopic dermatitis, asthma, and other diseases. Immune is also developing NanoCyclo, a nano-encapsulated formulation of cyclosporin, which is in late stage preclinical development for atopic dermatitis and psoriasis.
Company Info
Immune Pharmaceuticals Inc.
550 Sylvan Avenue
Englewood Cliffs NJ 07632
CEO: Elliot M. Maza
Phone: 201-464-2677
Immune Pharmaceuticals Inc. / IMNP FAQ
What is the stock price of Immune Pharmaceuticals Inc. today?
The current stock price of IMNP is 0.064 null. The price decreased by -61.21% in the last trading session.
What is the ticker symbol for Immune Pharmaceuticals Inc. stock?
The exchange symbol of Immune Pharmaceuticals Inc. is IMNP and it is listed on the Nasdaq exchange.
On which exchange is IMNP stock listed?
IMNP stock is listed on the Nasdaq exchange.
What is Immune Pharmaceuticals Inc. worth?
Immune Pharmaceuticals Inc. (IMNP) has a market capitalization of 2.78M null. This makes IMNP a Nano Cap stock.
Should I buy Immune Pharmaceuticals Inc. (IMNP) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of IMNP, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of IMNP, evaluating the profitability, health, valuation and growth aspects
- Immune Pharmaceuticals Inc. (IMNP) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- Immune Pharmaceuticals Inc. (IMNP) Sales and EPS estimates to see what analysts future expectations are.
- Immune Pharmaceuticals Inc. (IMNP) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- Immune Pharmaceuticals Inc. (IMNP) Insider and Institutional Ownership to learn about the owners and their transactions.
- Immune Pharmaceuticals Inc. (IMNP) Stock Chart to make your own analysis
- Immune Pharmaceuticals Inc. (IMNP) Latest news and press-releases to stay up to date.
Does Immune Pharmaceuticals Inc. (IMNP) stock pay dividends?
IMNP does not pay a dividend.
What is the Price/Earnings (PE) ratio of Immune Pharmaceuticals Inc. (IMNP)?
Immune Pharmaceuticals Inc. (IMNP) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.9).
IMNP Technical Analysis
IMNP Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to IMNP. IMNP has a bad profitability rating. Also its financial health evaluation is rather negative.
IMNP Financial Highlights
Over the last trailing twelve months IMNP reported a non-GAAP Earnings per Share(EPS) of -1.9000000000000001. The EPS increased by 81.42% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -82.21% | ||
| ROE | -392.98% | ||
| Debt/Equity | 0.19 |